



## MEDICAL CENTER

	Chapter	Clinical Practice
<b>Policy:</b> Pediatric Burn Hypermetabolic Protocol	Approval Date	12/10/19 CMT
	Review Date	1/1/2021

## Applicable to

VUH       VCH       DOT       VMG Off-site locations       VMG       VPH       Other

## Team Members Performing

All faculty & staff    Faculty & staff providing direct patient care or contact    MD    House Staff    APRN/PA    RN    LPN

Other:

## Content Experts

Authors: Ryan Stark, M.D.  
Assistant Professor of Pediatrics  
Division of Critical Care  
Department of Pediatrics

Daniel Barrett, APRN, MSN  
Division of Critical Care  
Department of Pediatrics

## Table of Contents

I.	Population: .....	2
II.	Assessment: .....	2
III.	Intervention/Treatment: .....	2
IV.	Other Considerations: .....	3
V.	References: .....	3

**I. Population:**

The hypermetabolic response in burn patients is characterized by hyperdynamic circulatory, physiologic, catabolic, and immune system responses.

The administration of agents that reduce the hypermetabolic response is an essential component of the management of pediatric burns.

**II. Assessment:**

Hypermetabolic management should be considered if a patient meets the following criteria:

1. TBSA greater than 20%<sup>1</sup>
2. Will require at least one operation
3. >72 hour after admission
4. Hemodynamically stable (not on pressors or requiring fluid boluses)

**III. Intervention/Treatment:**

**Propranolol**

1. Mechanism: Propranolol attenuates the hypermetabolism and reverses muscle-protein catabolism.<sup>2</sup>
2. Benefits: reductions in heart rate, cardiac work, lipolysis, hepatic steatosis, and skeletal muscle breakdown, and increased creation of skeletal muscle.

<b>Propranolol</b>	
Goal	Titrated to decrease baseline heart rate by 15-20% <sup>3</sup> Target HR: Mean HR*-15-20%
Dose	Initiate at 1mg/kg/day divided into 4 doses Reassess daily until target HR achieved. May increase to max of 4mg/kg/day divided into 4 doses

**Oxandrolone:**

1. Mechanism: The use of oxandrolone, an analog of testosterone possessing only 5% of its virilizing androgenic effects, enhances anabolism of muscle protein by improving the efficiency of protein synthesis.<sup>4</sup>
2. Benefits: Oxandrolone decreases loss of body weight and improves healing of the donor site wound.<sup>5</sup>

<b>Oxandrolone</b>	
Dose	0.1 mg/kg/dose BID

#### IV. Other Considerations:

##### **Nutrition:**

Adequate nutrition is imperative for the treatment of severely burned and critically ill patients to reduce the catabolic effects of burn injury. The Burn Nutrition Protocol should be followed.

##### **Pain Management:**

Pain management is important to decrease the hypermetabolic response. See the Pediatric Burn Protocol for recommendations.

##### **Glycemic Control:**

Glycemic control in critically ill patients leads to lower incidences of sepsis and mortality compared with patients who had poor glucose control. Monitor blood glucose levels and consider insulin for ICU level burn patients.

##### **Duration of Administration:**

Burn-induced hypermetabolic response lasts for at least 1 to 2 years after the injury.<sup>5,6</sup>

<sup>7</sup> Continuation of propranolol and oxandrolone after discharge should be considered when primary care is established.

#### V. References:

1. Deitch EA. Nutritional support of the burn patient. Crit Care Clin 1995; 11:735.
2. Finnerty, C. C., & Herndon, D. N. (2013). Is propranolol of benefit in pediatric burn patients?. Advances In Surgery, 47177-197.
3. Baron PW, Barrow RE, Pierre EJ, et al. Prolonged use of propranolol safely decreases cardiac work in burned children. J Burn Care Rehabil. 1997;18:223-227.
4. Hart DW, Wolf SE, Ramzy PI, et al. Anabolic effects of oxandrolone after severe burn. Ann Surg. 2001;233:556-564.
5. Demling RH, Orgill DP. The anticatabolic and wound healing effects of the testosterone analog oxandrolone after severe burn injury. J Crit Care. 2000;15:12-17.
6. Jeschke MG, Gauglitz GG, Kulp GA, et al. Long-term persistence of the pathophysiologic response to severe burn injury. PLoS One. 2011; 6:e21245. [PubMed: 21789167]
7. Herndon DN, Tompkins RG. Support of the metabolic response to burn injury. Lancet. 2004; 363:1895–902. [PubMed: 15183630]